Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trialResearch in context

Summary: Background: Dual inhibition of cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and programmed death ligand 1 (PD-L1) has been shown to be an effective treatment strategy in many cancers. We sought to determine the objective response rate of combination durvalumab (D) plus tremelimumab...

Full description

Saved in:

Bibliographic Details
Main Authors:	Abha A. Gupta, Anna Tinker, Derek Jonker, Rahma Jamal, Hal Hirte, Eric W. Winquist, Quincy Chu, Christian Kollmannsberger, Ralph Wong, Thierry Alcindor, Torsten O. Nielsen, Ming Tsao, Tricia R. Cottrell, Diane Provencher, John Hilton, Monika K. Krzyżanowska, Christine Elser, Sebastien Hotte, Joana Sederias, Siwei Zhang, Wei Tu, Janet Dancey
Format:	Article
Language:	English
Published:	Elsevier 2025-01-01
Series:	EClinicalMedicine
Subjects:	Checkpoint inhibitors Rare cancers Ovarian carcinoma
Online Access:	http://www.sciencedirect.com/science/article/pii/S2589537024005704
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trialResearch in context

Similar Items